He was diagnosed with
macroglobulinemia, a rare condition characterized by abnormally high levels of immunoglobulins in the blood.
他被诊断为巨球蛋白血症，这是一种罕见的疾病，其特征是血液中免疫球蛋白水平异常升高。
The patient's symptoms improved after treatment for
macroglobulinemia, which had been causing her recurrent infections.
在治疗了巨球蛋白血症后，患者的症状有所改善，这种疾病曾导致她反复感染。
Macroglobulinemia is often associated with multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow.
巨球蛋白血症常与多发性骨髓瘤相关，这是一种影响骨髓浆细胞的癌症。
His laboratory tests revealed a high level of M protein, a hallmark of
macroglobulinemia, in his blood sample.
实验室检查显示他的血液样本中M蛋白含量高，这是巨球蛋白血症的标志。
She underwent a bone marrow transplant to combat the aggressive form of
macroglobulinemia that was threatening her life.
她接受了骨髓移植以对抗威胁生命的严重型巨球蛋白血症。
Monitoring of electrolytes is crucial in managing patients with
macroglobulinemia, as the condition can lead to imbalances.
对于巨球蛋白血症患者，电解质监测至关重要，因为该病可能导致电解质失衡。
Symptoms of
macroglobulinemia include fatigue, frequent infections, and enlarged lymph nodes, which prompted her doctor's referral for testing.
巨球蛋白血症的症状包括疲劳、频繁感染和淋巴结肿大，这些促使她的医生推荐进行检查。
The drug therapy for
macroglobulinemia aims to lower the excessive immunoglobulin levels and alleviate related complications.
对巨球蛋白血症的药物治疗旨在降低过高的免疫球蛋白水平并缓解相关并发症。
Macroglobulinemia can be challenging to diagnose due to its nonspecific symptoms, but a thorough medical history and blood tests can help identify it.
由于巨球蛋白血症的症状不具特异性，因此诊断起来可能具有挑战性，但详细的病史和血液检查有助于识别。
Early detection and treatment of
macroglobulinemia are vital to prevent long-term complications and improve the patient's quality of life.
早期发现和治疗巨球蛋白血症对于防止长期并发症和提高患者生活质量至关重要。
Armed with innovative drugs, BeiGene goes from strength to strength overseasOn Feb 17, BeiGene Ltd, a mainland biotech company listed on both the Hong Kong stock exchange and the Nasdaq stock market, announced that the United States Food and Drug Administration has accepted to review its supplemental marketing application seeking approval for Brukinsa (zanubrutinib) for the treatment of adult patients with Waldenstrom's macroglobulinemia, a type of blood cancer.
凭借创新药物， BeiGene在海外不断取得突破2月17日，于香港联交所和纳斯达克上市的大陆生物科技公司 BeiGene宣布，美国食品药品监督管理局已受理其补充营销申请，该申请旨在批准 Brukinsa（zanubrutinib）用于治疗成年华氏巨球蛋白血症患者，这是一种血液癌症。
Additionally, very good partial response of Brukinsa, or close to complete response, reached 43 percent among patients with relapsed or refractory Waldenstrom macroglobulinemia, or WM, a rare type of cancer that begins in the white blood cells called lymphoplasmacytoids, and plasma cells, while that for Calquence and Imbruvica were only 29 percent and 16 percent respectively.
未经许可，严禁转发。QQ交流群：688169419